Precision Dosing: More is not always better
One of the cleaner ones, a 24-week randomized study of 279 mild-to-moderate Alzheimers patients, tested three doses against placebo and found a result no marketer would have designed: the lowest dose, 10 mL a day, beat placebo on both a cognitive scale and a global clinical rating, while the higher 30 and 60 mL doses improved the global rating but not cognition (Alvarez et al., Eur J Neurol 2006, randomized controlled trial)
Understanding insulin versus incretin-based therapies To fully grasp why Tresiba is not a GLP-1, it helps to understand the broader categories of diabetes medications and how they relate to each other
Semaglutide & tirzepatide show promise in #HFpEF, but challenges remain
It never changes when you add water
This article provides a comprehensive overview, drawing on verified scientific sources to ensure accuracy and balance